Cepheid Receives Health Canada Licence for Xpert® HIV-1 Viral Load XC
SUNNYVALE, Calif., June 4, 2025 /CNW/ -- Cepheid today announced that Health Canada has issued Cepheid a medical device licence for Xpert® HIV-1 Viral Load XC, a next-generation extended-coverage (XC) test intended to aid in assessing HIV viral load levels, which are used to monitor effectiveness of antiretroviral treatment.
Xpert® HIV-1 Viral Load XC dual target test provides extended strain coverage ensuring a high level of performance with a simple workflow to improve patient access to the standard of care and help achieve UNAIDS HIV targets by 2030.1
"Xpert® HIV-1 Viral Load XC leverages dual target technology to improve detection while maintaining the flexibility to be performed on-demand in as little as 90 minutes." said Vitor Rocha, President of Cepheid. "Access to the test can enhance patient care, as measurement of HIV viral load informs treatment plans while fast results enable earlier interventions with counseling and therapy."
The test is designed for use on any of Cepheid's GeneXpert® Systems which provide simple, reference lab quality PCR testing on location in laboratory environments at medical centers and hospitals or in community health clinics and physician offices.
Xpert® HIV-1 Viral Load XC will begin shipping to customers in Canada in June 2025.
Visit https://www.cepheid.com/en_CA for more information.
Malisa et al 2023 Nature Scientifc Reports | (2023) 13:4578https://doi.org/10.1038/s41598-023-31103-y
About CepheidBased in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company that is an operating company within Danaher Corporation's Diagnostics platform. Cepheid is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit http://www.cepheid.com.
IVD. In Vitro Diagnostic Medical Device. May not be available in all countries
For Cepheid Media Inquiries:Darwa Petersonmedia.communications@cepheid.com
SOURCE Cepheid
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2025/04/c5723.html
Erreur lors de la récupération des données
Connectez-vous pour accéder à votre portefeuille
Erreur lors de la récupération des données
Erreur lors de la récupération des données
Erreur lors de la récupération des données
Erreur lors de la récupération des données
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
7 hours ago
- Business Wire
Discover Yourself Named to Inc. 5000 for Second Time
EXCELSIOR, Minn.--(BUSINESS WIRE)--Discover Yourself, the world's largest distributor of the Insights Discovery® personality assessment, has once again been named to the Inc. 5000 list of America's Fastest-Growing Private Companies. This second-time honor places the Minnesota-based training firm alongside some of the country's most innovative and dynamic businesses. 'Being named to the Inc. 5000 is more than an award. It's proof our methods work, and that organizations everywhere are hungry for meaningful change.' Share The Inc. 5000 list is widely regarded as the hallmark of entrepreneurial success, celebrating innovation, customer impact and sustained revenue growth. Earning a spot on the list twice reflects Discover Yourself's strong performance, and its enduring ability to adapt and deliver value in a rapidly changing workplace environment. Easily the most colorful company on the Inc. 5000 list Founded by internationally recognized speaker, author and trainer Scott Schwefel, Discover Yourself transforms communication and teamwork by teaching the universal language of color. Through the Insights Discovery framework, individuals identify their unique blend of Fiery Red, Sunshine Yellow, Earth Green and Cool Blue energies, unlocking self-awareness and awareness of others. This approach enables participants to reduce misunderstandings, build stronger connections and collaborate more effectively. 'Most people who train with us have done other personality assessments but rarely use them. With ours, they start applying it immediately because every conversation, every email and every interaction gets better,' says Schwefel. Discover Yourself's programs — ranging from leadership development and sales training to executive coaching and team-building workshops — are trusted by global brands such as Caterpillar, 3M, Whirlpool, Zendesk and Workday. The company is actively expanding its reach with new online learning platforms, scalable virtual workshops and digital resources to make its programs accessible to teams anywhere in the world. Its reach spans all 50 states and more than 30 countries, powered in part by newly launched digital clones that can deliver on-demand training in 170 languages. Schwefel, one of only 60 global faculty certified to train other trainers, has personally taken 4,000 CEOs through Insights Discovery training, and has spoken to more than 2000 groups. His TED Talk has nearly four million views. He is also a popular keynote speaker worldwide. 'Being named to the Inc. 5000 is more than an award. It's proof our methods work, and that organizations everywhere are hungry for meaningful change,' comments Schwefel. Discover Yourself has grown from a two-person operation to 17 employees, who support a global network of more than 300 Insights Discovery certified facilitators. Clients reporting measurable boosts in collaboration, productivity and leadership capability. Visit Discover Yourself to take a one-minute quiz to discover where you fall in the color model. If you'd never experienced Insights Discovery and would like to learn more, contact Scott@
Business Wire
11 hours ago
- Business Wire
Elizabeth Walker Wadsworth, MD, MSCR, Joins Advanced ENT & Allergy, Bringing Expert ENT and Inspire® Sleep Apnea Care to Atlanta
ATLANTA--(BUSINESS WIRE)--Advanced ENT & Allergy is pleased to welcome Elizabeth Walker Wadsworth, MD, MSCR, a highly trained otolaryngologist from Atlanta's Buckhead community. Dr. Wadsworth provides comprehensive care for adults and children with conditions of the ear, nose, and throat, with special expertise in chronic sinusitis, hearing loss, and innovative treatments for sleep apnea, including the Inspire® implantable device. Dr. Wadsworth returning to Atlanta to treat the community she grew up in. Share Dr. Wadsworth earned her medical degree from Emory University School of Medicine and completed her residency in Otolaryngology–Head and Neck Surgery at the Medical University of South Carolina (MUSC), a top-ten residency program nationally. She is board-eligible in otolaryngology and is committed to delivering individualized, evidence-based care that improves breathing, hearing, and sleep health. 'As someone who grew up in Buckhead, it's a privilege to return home to care for patients in the city that shaped me,' said Dr. Wadsworth. 'Whether I'm helping a patient breathe easier, hear better, or finally sleep soundly, I strive to combine the best available treatments with genuine compassion and clear communication.' During her residency, Dr. Wadsworth gained extensive experience in advanced sinus surgery, ENT allergy management, pediatric and adult hearing loss, and the surgical implantation of the Inspire® upper airway stimulation system — an effective alternative for patients with obstructive sleep apnea who cannot tolerate CPAP therapy. Dr. Wadsworth is now accepting new patients at Advanced ENT & Allergy, located at 960 Johnson Ferry Rd NE, Suite 200, Atlanta, GA 30342. About Advanced ENT & Allergy Advanced ENT & Allergy is a leading provider of comprehensive ear, nose, and throat care in the Atlanta area. Our board-certified providers emphasize advanced treatment options, patient education, and individualized service in a welcoming, service-oriented environment.
Bloomberg
13 hours ago
- Bloomberg
Gilead Sciences CEO Says HIV Prevention Drug Offers Clear Value
Gilead Sciences Inc. Chief Executive Officer Daniel O'Day said the company's new HIV prevention drug Yeztugo should be able to gain favorable insurance coverage despite questions about how the Trump administration will handle recommendations for treatments like this. 'It's a very straightforward economic argument to prevent the disease,' O'Day said in an interview at Bloomberg's headquarters in New York Friday. 'No one wants HIV to continue to expand in this country.'
